ClinicalTrials.gg
RecruitingNCT06088121ATC-P001Updated Apr 23, 2026

Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia

An interventional study of ATNC MDD-V1 (Real TMS + Real Cog) and ATNC MDD-V1 (Sham TMS + Real Cog) in Alzheimer's Disease, Dementia and Brain Diseases, sponsored by Advanced Technology & Communications. Recruiting at 11 sites in South Korea. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Advanced Technology & Communications · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled May 2023, registered Sep 2023).
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 174 studies in Alzheimer Disease with a site in Korea, Republic of — 34 open to participants now, 46 under way, 16 of them phase 3. Alzheimer Disease · Korea, Republic of.

Planned enrollment
86th of 157
180 · median 206
Started
2023
with 4 others
No phase
27 of 174
9 open now
Primary completion
2027-01
later than 18 of 45 live
Registered
138th of 174
by date

Among the 174 studies in Alzheimer Disease with a site in Korea, Republic of, this one is the 86th largest by planned enrollment of the 157 interventional ones that give a count, is one of 5 that started in 2023, is one of 27 with no phase, reaches primary completion later than 18 of the 45 other live ones, and was the 138th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

34 of the 174 studies in Alzheimer Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 60 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 174 studies in Alzheimer Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The study tests the effect of the ATNC MDD-V1 on Alzheimer patients' cognitive function. The ATNC MDD-V1 uses non-invasive stimulation of both magnetic and cognitive training.

Read the detailed description

The ATNC MDD-V1 system is a combined system of Transcranial Magnetic Stimulation and cognitive training and is a non-invasive therapeutic system for the improvement of Alzheimer patients' cognitive function.

A potential participant will undergo screening procedures to confirm eligibility to participate in the study, followed by randomization procedure to one of the study groups - treatment or sham (placebo) Patient will attend the clinic 5 times a week for 6 weeks, approximately an hour every day for treatment/sham. The patient will be required to return to the clinic for follow-up.

Up to 180 patients will be enrolled in up to 11 clinical sites in the Republic Korea.

03

Conditions studied

  • Alzheimer's Disease
  • Dementia
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Neurodegenerative Diseases
  • Neurocognitive Disorders
  • Mental Disorder

Keywords

  • TMS
  • Cognitive Stimulation
  • ATNC MDD-V1
  • Dementia
04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who started drug treatment with an acetylcholinesterase inhibitor at least 2 months before participating in the clinical trial and can participate in the clinical trial without changing the dose during the trial period.
  2. Male or female age 60-85 years.
  3. Patients diagnosed with mild stage of Alzheimer's Disease, according to the NIA-AA (2011) diagnosis.
  4. A patient whose dementia was confirmed to be due to Alzheimer's disease by amyloid PET-CT.
  5. score 21 to 26.
  6. CDR 1 or GDS 3.

    ※ For subjects who are excluded from screening based on criteria 5 or 6, if the investigator judges that the subject is likely to be eligible, one repeat screening may be performed.

  7. A patient who is deemed physically eligible for the clinical trial based on medical records and physical examination.
  8. A patient who is unable to provide voluntary for the clinical trial due to impaired decision-making capacity, for whom a legally authorized representative provides consent for participation, and who can attend follow-up visits with a caregiver.
  9. Patients who agreed to participate in all 24-week clinical trials.
  10. Patients with normal ability to see and hear letters.
  11. Patients who speak Korean as their mother tongue

Exclusion criteria

Exclusion Criteria:

  1. Patients with central nervous system (CNS) disorders that may affect cognitive function (such as cerebrovascular diseases including vascular dementia, subdural hematoma, normal pressure hydrocephalus, brain tumors, CNS infections like or syphilis, head trauma, Huntington's disease, Parkinson's disease, etc.) where cognitive decline may be explained by other causes, or in whom dementia types other than Alzheimer's disease are suspected.
  2. Patients who have been unconscious due to brain surgery or concussion, or who have signs or symptoms of cranial pressure elevation on neurologic examination.
  3. History of Epileptic Seizures or Epilepsy.
  4. Patients with a history of drug abuse, including alcohol, in the past 5 years from the time of screening.
  5. Patients with schizophrenia, schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, post-traumatic stress, severe anxiety, mental retardation, disorder.
  6. Patients with abnormal vitamin B12, folic acid deficiency, or thyroid stimulating hormone (TSH) test results that were considered by the investigator to affect or are caused by the severity of dementia.
  7. Patients with metal implants in the head, (i.e. cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants.
  8. Cardiac pacemakers.
  9. Implanted medication pumps.
  10. Intracardiac lines.
  11. Patients who are currently taking medications that lower the convulsive seizure threshold.
  12. Significant heart disease.
  13. Patients with severe renal or hepatic impairment※, referring to conditions that significantly affect daily living (e.g., stage 4 chronic kidney disease), with the assessment based on the investigator's judgment.
  14. for performing MRI scanning.
  15. Contraindication for performing amyloid PET-CT scanning.
  16. Patients who do not consent to TMS treatment and participation in this clinical trial.
  17. Patients who participated in other clinical trials 3 months before participating in this clinical trial.

    ※ Subjects who participate in non-interventional studies (such as observational studies) that do not affect the subject's disease or symptoms may be enrolled in the study.

  18. Patients with a history of TMS treatment within the last 2 years before participating in this clinical trial.
  19. Patients judged by the investigator to be unsuitable for participation in clinical trials for other reasons.

    ※ If the test subject is unable to visit according to the research plan due to unavoidable personal circumstances during the screening period, it will be treated as a screening dropout, and the patient can participate in the study after re-agreeing according to the future schedule.

  20. Patients with a history of malignant tumors within the last 5 years.

    - Participation is possible if more than 5 years have elapsed without recurrence after the decision to be cured (The point of complete removal of the tumor through surgery or the end of chemotherapy, etc.).

  21. Patients who need to take medications suggested in concomitantly contraindicated drugs.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Active comparator
    ATNC MDD-V1

    ATNC MDD-V1 treatment, synchronized TMS and cognitive training stimulation

    Device: ATNC MDD-V1 (Real TMS + Real Cog) · Device: ATNC BN-V1 · Device: ATNC BN-V2

  • Sham comparator
    Sham TMS + Real Cog

    The Control arm subjects will receive daily treatments five days a week for 6 consecutive weeks of Sham treatment of TMS and real cognitive training which is similar to the real treatment in visit frequency and procedure.

    Device: ATNC MDD-V1 (Sham TMS + Real Cog) · Device: ATNC BN-V1 · Device: ATNC BN-V2

Interventions

  • DeviceATNC MDD-V1 (Real TMS + Real Cog)

    Synchronized TMS and cognitive stimulation to 6 brain areas.

    Also known as: ATNC MDD-V1, Brain Sense & Brain Cog

  • DeviceATNC MDD-V1 (Sham TMS + Real Cog)

    Sham device, has the same appearance and sound as the real device, combined with real cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.

    Also known as: sham

  • DeviceATNC BN-V1

    The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).

    Also known as: Brain Navigation System V1

  • DeviceATNC BN-V2

    The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).

    Also known as: Brain Navigation System V2

06

What researchers measure

Primary outcomes

  1. Alzheimer's Disease Assessment Scale-Cognition Score (Efficacy)

    Change from Baseline to 24 weeks in ADAS-Cog score. ADAS-Cog: Alzheimer's Disease Assessment Scale - Cognitive

    Time frame: Week 24

Secondary outcomes

  1. Alzheimer's Disease Assessment Scale-Cognitive(ADAS-cog) Score (Efficacy)

    Change from Baseline to 7,12 weeks in ADAS-Cog score. ADAS-Cog: Alzheimer's Disease Assessment Scale - Cognitive

    Time frame: Week 7, 12

  2. Korean-Mini Mental State Examination-2nd Edition(K-MMSE-2)(Efficacy)

    Change from Baseline to 7, 12 and 24 weeks in K-MMSE-2. K-MMSE-2: Korean-Mini Mental State Examination-2nd Edition

    Time frame: Week 7, 12, 24

  3. Clinical Dementia Rating(CDR)(Efficacy)

    Change from Baseline to 7, 12 and 24 weeks in CDR. CDR: Clinical Dementia Rating

    Time frame: Week 7, 12, 24

  4. Global Deterioration Scale(GDeps)(Efficacy)

    Change from Baseline to 7, 12 and 24 weeks in GDeps. GDeps: Global Deterioration Scale

    Time frame: Week 7, 12, 24

  5. Clinical Global Impression of Change(CGIC)(Efficacy)

    Change from Baseline to 7, 12 and 24 weeks in CGIC CGIC: Clinical Global Impression of Change

    Time frame: Week 7, 12, 24

  6. Korean-Instrumental Activities of Daily Living(K-IADL)(Efficacy)

    Change from Baseline to 7, 12 and 24 weeks in K-IADL. K-IADL: Korean-Instrumental Activities of Daily Living

    Time frame: Week 7, 12, 24

Other outcomes

  1. Adverse events(AE's)(Safety)

    Adverse events (AE's), including serious adverse events (SAEs) occurring at any time during the trial and follow-up.

    Time frame: Week 24

07

Study locations

11 of 11 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Jan 2027, 44 months after the start.

Of 77 industry-sponsored interventional studies with no phase under Alzheimer Disease, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's planned 44 months is above that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2023
First posted
Oct 18, 2023
StartActual
May 15, 2023
Primary completionEst.
Jan 15, 2027
CompletionEst.
Jun 30, 2027
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06088121
Lead sponsor
Advanced Technology & Communications
Collaborators
Chungnam National University Hospital, Korea University Anam Hospital, Dong-A University Hospital, Chonnam National University Hospital, Chonbuk National University Hospital, Chung-Ang University Gwangmyeong Hospital, Yeungnam University Hospital, Inje University Ilsan Paik Hospital, National Health Insurance Service Ilsan Hospital, Konkuk University Medical Center
Responsible party
Sponsor
First posted
Oct 18, 2023
Start date
May 15, 2023
Primary completion
Jan 15, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Apr 23, 2026

Study contacts

Shin Jinwoo
Contact
jinwoo.shin@atnci.com
+82314450566
Hyunah Lee
Contact
hyunah.lee@atnci.com
+821079373566
Ae Young MD LEE, PhD
principal investigator · Chungnam National University Hospital
Kun Woo MD Park, PhD
principal investigator · Korea University Anam Hospital
Deye MD Yoon, PhD
principal investigator · Dong-A University Hospital
Goun MD Kim, PhD
principal investigator · Chonbuk National University Hospital
Su-Hyun MD Jo, PhD
principal investigator · Chonnam National University Hospital
Mincheol MD Park, PhD
principal investigator · Chung-Ang University Gwangmyeong Hospital
Inwook MD Song, PhD
principal investigator · Incheon St.Mary's Hospital
Miyoung MD Park, PhD
principal investigator · Yeungnam University Hospital
Younggeon MD Lee, PhD
principal investigator · Inje University Ilsan Paik Hospital
Sohun MD Yoon, PhD
principal investigator · National Health Insurance Service Ilsan Hospital
Yeonsil MD Moon, PhD
principal investigator · Konkuk University Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion